I. COMMENCED TRADING IN NOVEMBER

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

INITIAL OFFERINGS

There were no initial public offerings in November.

Total: $0M

Number of IPOs in November: 0

Average value of November IPOs: $0M

Number of IPOs for 2001: 7

Total raised in IPOs in 2001: $207.05M

Average value of IPOs in 2001: $29.58M

FOLLOW-ON OFFERINGS

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

ICOS Corp. (ICOS)¹

6/26

11/8

5.5

$57

59

CS First Boston (co-lead)
Merrill Lynch & Co. (co-lead)
SG Cowen Securities Corp.
Banc of America Securities LLC
Robertson Stephens Inc.

$313.5

$297.3

ILEX Oncology Inc. (ILXO)²

10/29

11/15

5.75S

$24

31.5

CIBC World Markets (co-lead)
UBS Warburg LLC (co-lead)
U.S. Bancorp Piper Jaffray

$138

$129.1

Labopharm Inc. (Canada; TSE:DDS)³

10/29

11/8

5.2S

C$6.75

N/A

Research Capital Corp.
CIBC World Markets Corp.
National Bank Financial Inc.
TD Securities Inc.

C$35.1
(US$22.2)

N/A

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; TSE = Toronto Stock Exchange

N/A = Not available, applicable or reported.

¹ ICOS' underwriters have an option for another 815,789 shares to cover overallotments.

² ILEX's offering includes the full exercise of the underwriters' overallotment option for 750,000 shares.

³ Labopharm's offering includes 1.2M shares that were issued as a result of an option to the underwriters of the offering.

Total: $473.7M

Number of follow-on offerings in November: 3

Average value of November follow-ons: $157.9

Number of follow-on offerings in 2001: 34

Total raised in follow-ons in 2001: $2,952.41M

Average value of follow-ons in 2001: $86.8M

II. FILED AND PENDING

Company (Symbol/Proposed Symbol)#*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

AgraQuest Inc. (AGRQ)¹

8/3

N/A

N/A

N/A

Merrill Lynch & Co.
Stephens Inc.
First Union Securities Inc.

$75

Antisense Therapeutics Ltd. (Australia)²

11/21**

N/A

N/A

N/A

N/A

A$13
(US$6.73)

APBiotech (APBI; unit of Nycomed Amersham plc)³

10/3/00

18.2S

$15-17

208.6

Morgan Stanley Dean Witter (co-lead)
Goldman, Sachs & Co. (co-lead)
Chase H&Q
Salomon Smith Barney

$291.2

CombiMatrix Corp. (CLMX)⁴

11/22/00

N/A

N/A

N/A

Salomon Smith Barney (co-lead)
JP Morgan & Co. (co-lead)

$100

diaDexus Inc. (DDXS)⁵

11/20

7S

$12-14

31.1

Lehman Brothers Inc.
CIBC World Markets Corp.
Robertson Stephens Inc.
Fidelity Capital Markets

$91

NeoGenesis Pharmaceuticals Inc. (NGPI)⁶

11/19

N/A

N/A

N/A

JP Morgan & Co.
Bear, Stearns & Co. Inc.
SG Cowen Securities

$115

Northwest Biotherapeutics Inc. (NWBT)⁷

8/13

3.5S

$8-$10

16.5

C.E. Unterberg, Towbin
Fahnestock & Co. Inc.
Roth Capital Partners LLC

$31.5

Ribapharm Inc. (RIBA)⁸

5/15

18S

$13-15

N/A

UBS Warburg LLC
CIBC World Markets Corp.

$252

Xcyte Therapies Inc. (XCYT)⁹

12/22

N/A

N/A

N/A

SG Cowen Securities Corp. (co-lead)
U.S. Bancorp Piper Jaffray (co-lead)
Dain Rauscher Inc.
First Security Van Kasper Inc.

$86.2

ZymoGenetics Inc. (ZGEN)¹⁰

9/10

N/A

N/A

N/A

Lehman Brothers Inc. (co-lead)
Merrill Lynch & Co. (co-lead)
Bear, Stearns & Co. Inc.
Pacific Growth Equities Inc.

$180

FOLLOW-ON OFFERINGS

Antigenics Inc. (AGEN)¹¹

11/27

N/A

N/A

N/A

N/A

$100

BioMarin Pharmaceutical Inc. (BMRN)¹²

11/12

6S

$12.12

42

UBS Warburg LLC
CIBC World Markets Corp.
U.S. Bancorp Piper Jaffray

$72.7

Cell Pathways Inc. (CLPA)¹³

2/7

N/A

N/A

N/A

N/A

$25

Cerus Corp. (CERS)¹⁴

8/13

N/A

N/A

15.7

N/A

$300

CollaGenex Pharmaceuticals Inc. (CGPI)¹⁵

10/26

0.965S

$8.01

N/A

N/A

$7.7

Cytogen Corp. (CYTO)¹⁶

10/26

10S

$2.50

78.9

N/A

$25

Exelixis Inc. (EXEL)¹⁷

7/30

N/A

N/A

49.2

N/A

$150

Genaissance Pharmaceuticals Inc. (GNSC)¹⁸

10/18

N/A

N/A

22.8

N/A

$35

Genaera Corp. (GENR)¹⁹

11/21

N/A

N/A

N/A

N/A

$50

Inex Pharmaceuticals Corp. (Canada; TSE:IEX)²⁰

11/26

6.145S

C$7
(US$4.40)

N/A

BMO Nesbitt Burns Inc.
Raymond James Ltd.
RBC Capital Markets Inc.
Yorkton Securities Inc.
Dlouhy Merchant Group Inc.

C$43
(US$27)

InSite Vision Inc. (AMEX:ISV)²¹

2/2

N/A

N/A

N/A

Ladenburg Thalmann & Co.
(placement agent)

$40

Matrix Pharmaceuticals Inc. (MATX)²²

5/25

N/A

N/A

26

N/A

$30

Medicure Inc. (Canada; CDNX: MPH)²³

11/14

N/A

N/A

N/A

N/A

C$10
(US$6.3)

Microcide Pharmaceuticals Inc. (MCDE)²⁴

2/12

N/A

N/A

N/A

N/A

$35

Myriad Genetics Inc. (MYGN)²⁵

11/9

N/A

N/A

N/A

N/A

$250

NeoTherapeutics Inc. (NEOT)²⁶

1/3

N/A

N/A

21.9

N/A

$50

Neurocrine Biosciences Inc. (NBIX)²⁷

11/13

3.25S

$44.97

29.5

Deutsche Banc Alex. Brown (co-lead)
Credit Suisse First Boston (co-lead)
CIBC World Markets Corp.
Lehman Brothers Inc.
UBS Warburg LLC

$146.2

SciClone Pharmaceuticals Inc. (SCLN)²⁸

11/6

N/A

N/A

N/A

N/A

$20

Theratechnologies Inc. (Canada; TSE:TH)²⁹

11/27

2.5S

C$10.25

N/A

Yorkton Securities Inc.

C$26
(US$16)

Tularik Inc. (TLRK)³⁰

8/14

N/A

N/A

49.2

N/A

$250

Valentis Inc. (VLTS)³¹

9/27

N/A

N/A

29.9

N/A

$45

Vysis Inc. (VYSI)³²

8/8

1S

$25.96

11.2

UBS Warburg LLC
First Union Securities Inc.
Pacific Growth Equities Inc.

$26

III. WITHDRAWN AND POSTPONED

Company (Symbol/Proposed Symbol)*

Date Filed/Date Pulled

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

BioNumerik Pharmaceuticals Inc. (BNPI)³³

3/2
11/20

N/A

N/A

N/A

Morgan Stanley Dean Witter
UBS Warburg LLC
SG Cowen Securities Corp.

$50

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; CDNX = Canadian Stock Exchange; TSE = Toronto Stock Exchange

¹ AgraQuest filed a registration statement with the SEC to raise $75M in an IPO.

² Antisense, a spin-off of Circadian Technologies Ltd., is seeking to raise US$6.73M in an IPO conducted on Australia's stock exchange.

³ APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

⁴ CombiMatrix did not disclose any further details.

⁵ diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

⁶ NeoGenesis filed for an IPO to raise $115M.

⁷ Northwest filed in August for an IPO expected to raise $48.3M. It amended the filing in October to raise $35M, and amended it in November to raise about $31.5M. The underwriter has an overallotment option for an additional 525,000 shares.

⁸ Ribapharm's IPO originally was proposed in June 2000. The company amended its prospectus on May 15. The value, $252M, is based on the offering of 18M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares.

⁹ Xcyte did not disclose any further details.

¹⁰ ZymoGenetics filed to raise $180M in an IPO.

¹¹ Antigenics filed a shelf registration covering the issuance of various types of securities, including secured and unsecured debt securities, preferred stock, depository shares and common stock.

¹² BioMarin's underwriters have an overallotment option for up to 900,000 shares.

¹³ Cell Pathways filed a shelf registration for the sale of $25M in common stock.

¹⁴ Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

¹⁵ The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01.

¹⁶ Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration.

¹⁷ Exelixis filed a shelf registration to sell up to $150M in common stock.

¹⁸ Genaissance filed a shelf registration to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M.

¹⁹ Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock.

²⁰ Inex intends to raise about US$27M in the offering, which is expected to close on or about Dec. 13.

²¹ InSite filed a shelf registration in February to sell $40M in stock.

²² Matrix filed a shelf registration covering up to $30M in securities.

²³ Medicure plans to offer units, each consisting of one common share and one common share purchase warrant exercisable for a period of 24 months. The price will be determined in the context of the market.

²⁴ Microcide filed a shelf registration for the sale of up to $35M in securities. (Microcide is now Essential Therapeutics Inc., formed through its merger with The Althexis Company Inc.)

²⁵ Myriad filed a shelf registration statement for the sale of up to $250M of various types of securities.

²⁶ NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. In May, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. In November, it placed 950,000 shares, raising $3.8M.

²⁷ Neurocrine filed to sell 3.25M shares. The offering's value, $146.2M, is based on the Nov. 27 closing stock price of $44.97. The underwriters have an overallotment option for 487,500 shares.

²⁸ SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering.

²⁹ Theratechnologies' underwriters have an option to purchase an additional 382,000 common shares. The deal is expected to close Dec. 13.

³⁰ Tularik filed to sell up to $250M in common stock and debt securities.

³¹ Valentis filed to sell up to $45M worth of equity warrants, preferred and common stock through a shelf registration statement.

³² Vysis registered to sell 4M shares, 3M of which will be sold by shareholder BP plc. The value of the offering, $26M, is based on the closing stock price of $25.96 on Aug. 7. The underwriters have an overallotment option for 600,000 shares. (Vysis is now being purchased by Abbott Laboratories.)

³³ BioNumerik withdrew its IPO, citing market conditions.